| abstract |
Phenyl urea and phenyl thiourea derivatives of formula (I): in which X and Y independently represent CH or nitrogen, provided that X and Y do not both represent CH; Z represents oxygen or sulphur; R1 represents (C1-6)alkyl, (C2 6)alkenyl or (C1-6)alkoxy, any of which may be optionally substituted; halogen, R7CO- or NR8R9CO-; R2, R3, R4, R5 and R6 independently represent (C1 6)alkyl, (C2-6)alkenyl, (C1-6)alkoxy or (C1-6)alkylthio, any of which may be optionally substituted; hydrogen, halogen, nitro, cyano, aryloxy, aryl(C1 6)alkyloxy, aryl(C1-6)alkyl, R7CO-, R7SO2NH-, R7CON(R10)-, NR8R9-, NR8R9CO-, COR8 or heterocyclyl; provided that at least one of R2, R3, R4, R5 and R6 is other than hydrogen; or an adjacent pair of R2, R3, R4, R5 and R6 together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring; R7 is (C1-6)alkyl or aryl; R8 and R9 independently represent hydrogen, (C1-6)alkyl, aryl or aryl(C1-6)alkyl; R10 is hydrogen or (C1-6)alkyl; and n is 0, 1, 2, 3 or 4; or a pharmaceutically acceptable salt thereof. The present invention provides phenyl urea and phenyl thiourea derivatives which are non-peptide antagonists of the human HFGAN72 receptor. In particular, these compounds are of potential use in the treatment of obesity including obesity observed in Type 2 (noninsulin-dependent) diabetes patients and/or sleep disorders. |